Vivos Therapeutics (NASDAQ:VVOS) Stock Price Down 6.7% – Here’s What Happened

Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares dropped 6.7% during mid-day trading on Monday . The company traded as low as $1.51 and last traded at $1.52. Approximately 50,965 shares were traded during trading, a decline of 52% from the average daily volume of 106,025 shares. The stock had previously closed at $1.63.

Analysts Set New Price Targets

VVOS has been the topic of several research reports. HC Wainwright initiated coverage on Vivos Therapeutics in a research report on Monday, November 17th. They issued a “buy” rating and a $7.00 target price on the stock. Ascendiant Capital Markets lowered their price target on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, January 21st. Finally, Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 1st. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $4.92.

Vivos Therapeutics Trading Down 6.7%

The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31. The company has a 50-day moving average price of $1.88 and a 200-day moving average price of $2.70. The company has a market capitalization of $15.91 million, a price-to-earnings ratio of -0.86 and a beta of 6.93.

Institutional Investors Weigh In On Vivos Therapeutics

Hedge funds have recently modified their holdings of the business. Acorn Wealth Advisors LLC acquired a new stake in shares of Vivos Therapeutics in the fourth quarter worth $30,000. XTX Topco Ltd bought a new stake in Vivos Therapeutics in the 2nd quarter valued at $65,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Vivos Therapeutics in the second quarter valued at about $220,000. DRW Securities LLC grew its position in Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after buying an additional 74,441 shares in the last quarter. Finally, Connective Capital Management LLC acquired a new stake in Vivos Therapeutics during the third quarter worth about $620,000. 26.35% of the stock is owned by institutional investors.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.